Atomoxetine

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Austria: Strattera; Belgium: Strattera; Cyprus: Strattera; Czech Republic: Strattera; Denmark: Strattera; Estonia: Strattera; Finland: Strattera; Germany: Strattera; Greece: Strattera; Hungary: Strattera; Ireland: Strattera; Italy: Strattera; Latvia: Strattera; Malta: Strattera; Netherlands: Strattera; Poland: Strattera; Portugal: Strattera; Romania: Strattera; Slovakia: Strattera; Slovenia: Strattera; Spain: Strattera; Sweden: Strattera; UK: Strattera.

North America

Canada: Strattera; USA: Strattera.

Latin America

Argentina: Recit, Strattera; Mexico: Strattera.

Drug combinations

Chemistry

Atomoxetine Hydrochloride: C~17~H~21~NO HCl. Mw: 291.82. (-)-N-Methyl-3-phenyl-3-(o-tolyloxy)propylamine hydrochloride. CAS-82248-59-7; CAS-83015-26-3 (tomoxetine)(2001).

Pharmacologic Category

Central Nervous System Agents, Miscellaneous; Selective Norepinephrine-Reuptake Inhibitor. (ATC-Code: N06BA09).

Mechanism of action

Selectively inhibits the reuptake of norepinephrine.

Therapeutic use

Treatment of attention-deficit hyperactivity disorder.

Pregnancy and lactiation implications

Use only if potential benefit to the mother outweighs possible risk to fetus. Use with caution during lactation.

Unlabeled use

Contraindications

Hypersensitivity to atomoxetine or any component of the formulation. Use with or within 14 days of MAO inhibitors. Narrow-angle glaucoma.

Warnings and precautions

Use with caution in pediatric patients (may be an increased risk of suicidal ideation). Aggressive behavior (particularly with the initiation of therapy). Allergic reactions (angioneurotic edema, urticaria, and rash) may occur. Risk of cardiovascular events in patients with serious cardiac problems. Rarely, severe hepatotoxicity may develop (use with caution in hepatic impairment and in poor metabolizers of CYP2D6-metabolized drugs). Priapism might occur (rarely). Does not worsen anxiety in existing anxiety disorders or tics related to Tourette’s disorder. Use with caution in hypertension and other cardiovascular conditions that might be exacerbated by increases in blood pressure or heart rate. Use caution in history of psychotic illness or bipolar disorder (may induce mixed/manic disorder or psychotic symptoms). Atomoxetine is not approved for major depressive disorder. Use cautiously in history of urinary retention or bladder outlet obstruction (may cause urinary retention/hesitancy).

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart